Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPI 287

Drug Profile

TPI 287

Alternative Names: ARC-100; NBT 287; TPI-287

Latest Information Update: 11 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tapestry Pharmaceuticals
  • Developer Cortice Biosciences; H. Lee Moffitt Cancer Center and Research Institute; Tapestry Pharmaceuticals; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Van Andel Research Institute
  • Class Antidementias; Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Microtubule protein modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Glioblastoma
  • Phase I/II Malignant melanoma
  • Phase I Alzheimer's disease; Corticobasal degeneration; Non-small cell lung cancer; Progressive supranuclear palsy
  • No development reported Cancer; Medulloblastoma; Neuroblastoma
  • Discontinued Pancreatic cancer; Prostate cancer

Most Recent Events

  • 22 May 2019 Cortice Biosciences terminates a phase I trial for Breast cancer (Metastatic disease) in USA due to lack of funding by company providing TPI 287 (IV) (NCT02187822)
  • 24 Jun 2018 Biomarkers information updated
  • 03 Apr 2018 Cortice Biosciences temporarily suspends a phase II trial for Glioblastoma (recurrent; combination therapy) for financial reasons in USA (NCT01933815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top